iCAD (ICAD) 10-Q 11 May 22 2022 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2022	May 10, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Registrant Name	ICAD INC
Entity Central Index Key	0000749660
Current Fiscal Year End Date	--12-31
Document Quarterly Report	true
Document Transition Report	false
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Trading Symbol	ICAD
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Address, State or Province	NH
Entity Shell Company	false
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		25,181,857
Entity Tax Identification Number	02-0377419
Entity File Number	001-09341
Entity Incorporation, State or Country Code	DE
Entity Address, City or Town	Nashua
Entity Address, Address Line One	98 Spit Brook Road, Suite 100
Entity Address, Postal Zip Code	03062
City Area Code	603
Local Phone Number	882-5200

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 29,798	$ 34,282
Trade accounts receivable, net of allowance for doubtful accounts of $573 in 2022 and $268 in 2021	10,309	8,891
Inventory, net	4,736	4,171
Prepaid expenses and other current assets	3,090	2,962
Total current assets	47,933	50,306
Property and equipment, net of accumulated depreciation of $7,192 in 2022 and $7,106 in 2021	947	882
Operating lease assets	859	1,059
Other assets	104	899
Intangible assets, net of accumulated amortization of $8,776 in 2022 and $8,724 in 2021	640	683
Goodwill	8,362	8,362
Total assets	58,845	62,191
Current liabilities:
Accounts payable	2,681	2,779
Accrued and other expenses	5,128	5,642
Lease payable—current portion	887	889
Deferred revenue	5,765	5,652
Total current liabilities	14,461	14,962
Lease payable, long-term portion	54	266
Deferred revenue, long-term portion	571	441
Deferred tax	6	5
Total liabilities	15,092	15,674
Commitments and Contingencies (Note 13)
Stockholders' equity:
Preferred stock, $0.01 par value: authorized 1,000,000 shares; none issued
Common stock, $0.01 par value: authorized 60,000,000 shares; issued 25,359,175 as of March 31, 2022 and 25,326,086 as of December 31, 2021.	253	253
Additional paid-in capital	301,640	300,859
Accumulated deficit	(256,725)	(253,180)
Treasury stock at cost, 185,831 shares in 2021 and 2020	(1,415)	(1,415)
Total stockholders' equity	43,753	46,517
Total liabilities and stockholders' equity	$ 58,845	$ 62,191

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for doubtful accounts on trade accounts receivable	$ 573	$ 268
Property and equipment, accumulated depreciation and amortization	7,192	7,106
Intangible assets, accumulated amortization	$ 8,776	$ 8,724
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	60,000,000	60,000,000
Common stock, shares issued	25,359,175	25,326,086
Common stock, shares outstanding	25,173,344	25,140,255
Treasury stock, shares	185,831	185,831

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue:
Total revenue	$ 7,523	$ 8,644
Cost of revenue:
Total cost of revenue	2,211	2,355
Gross profit	5,312	6,289
Operating expenses:
Engineering and product development	2,275	2,192
Marketing and sales	3,565	3,424
General and administrative	2,931	2,151
Amortization and depreciation	63	55
Total operating expenses	8,834	7,822
Loss from operations	(3,522)	(1,533)
Interest expense	(9)	(112)
Other income (expense)	(13)	2
Other expense, net	(22)	(110)
Loss before income tax expense	(3,544)	(1,643)
Tax expense		0
Net loss and comprehensive loss	$ (3,545)	$ (1,643)
Net loss per share:
Basic	$ (0.14)	$ (0.07)
Diluted	$ (0.14)	$ (0.07)
Weighted average number of shares used in computing loss per share:
Basic	25,160	23,929
Diluted	25,160	23,929
Product [Member]
Revenue:
Total revenue	$ 4,560	$ 5,557
Cost of revenue:
Total cost of revenue	1,087	1,409
Service [Member]
Revenue:
Total revenue	2,963	3,087
Cost of revenue:
Total cost of revenue	1,049	867
Amortization and depreciation [Member]
Cost of revenue:
Total cost of revenue	$ 75	$ 79

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flow from operating activities:
Net loss	$ (3,545)	$ (1,643)
Adjustments to reconcile net loss to net cash used for operating activities:
Amortization	53	58
Depreciation	86	76
Bad debt provision	305	0
Stock-based compensation	655	935
Deferred tax	1	0
Amortization of debt discount and debt costs	0	12
Changes in operating assets and liabilities:
Accounts receivable	(1,723)	(622)
Inventory	(565)	647
Prepaid and other assets	653	(89)
Accounts payable	(98)	(1,617)
Accrued expenses	(514)	(1,313)
Deferred revenue	243	(7)
Total adjustments	(904)	(1,920)
Net cash used for operating activities	(4,449)	(3,563)
Cash flow from investing activities:
Additions to patents, technology and other	(10)	0
Additions to property and equipment	(151)	(262)
Net cash used for investing activities	(161)	(262)
Cash flow from financing activities:
Proceeds from option exercises pursuant to stock option plans	66	270
Proceeds from issuance of common stock pursuant to Employee Stock Purchase Plans	60	47
Proceeds from issuance of common stock, net	0	23,229
Net cash provided by financing activities	126	23,546
(Decrease) increase in cash and cash equivalents	(4,484)	19,721
Cash and cash equivalents, beginning of period	34,282	27,186
Cash and cash equivalents, end of period	29,798	46,907
Supplemental disclosure of cash flow information:
Interest paid	9	92
Taxes paid	$ 0	$ 0

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]
Beginning Balance at Dec. 31, 2020	$ 30,525	$ 236	$ 273,639	$ (241,935)	$ (1,415)
Beginning Balance, shares at Dec. 31, 2020		23,694,406
Issuance of common stock relative to vesting of restricted stock	0	$ 0	0
Issuance of common stock relative to vesting of restricted stock, shares		20,000
Issuance of common stock, net	23,229	$ 14	23,215
Issuance of common stock, net, shares		1,393,738
Issuance of common stock pursuant to stock option plans	271	$ 1	270
Issuance of common stock pursuant to stock option plans, shares		28,934
Issuance of common stock pursuant Employee Stock Purchase Plan	47		47
Issuance of common stock pursuant Employee Stock Purchase Plan, shares		6,354
Stock-based compensation	935		935
Net loss	(1,643)			(1,643)
Ending Balance at Mar. 31, 2021	53,364	$ 251	298,106	(243,578)	(1,415)
Ending Balance, shares at Mar. 31, 2021		25,143,432
Beginning Balance at Dec. 31, 2021	46,517	$ 253	300,859	(253,180)	(1,415)
Beginning Balance, shares at Dec. 31, 2021		25,326,086
Issuance of common stock relative to vesting of restricted stock	0	$ 0	0
Issuance of common stock relative to vesting of restricted stock, shares		875
Issuance of common stock pursuant to stock option plans	66	$ 0	66
Issuance of common stock pursuant to stock option plans, shares		22,833
Issuance of common stock pursuant Employee Stock Purchase Plan	60	$ 0	60
Issuance of common stock pursuant Employee Stock Purchase Plan, shares		9,381
Stock-based compensation	655		655
Net loss	(3,545)			(3,545)
Ending Balance at Mar. 31, 2022	$ 43,753	$ 253	$ 301,640	$ (256,725)	$ (1,415)
Ending Balance, shares at Mar. 31, 2022		25,359,175

Organization and Business

Organization and Business	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business	Note 1 – Organization and Business Basis of Presentation The accompanying condensed consolidated financial statements of iCAD, Inc. and its subsidiaries (together “iCAD” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting period and disclosure of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. It is reasonably possible that changes may occur in the near term that would affect management’s estimates with respect to assets and liabilities. In the opinion of the Company’s management, these unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position of the Company at March 31, 2022, the results of operations of the Company for the three-month periods ended March 31, 2022 and 2021, cash flows of the Company for the three-month periods ended March 31, 2022 and 2021, and stockholders’ equity for the Company for the three-month periods ended March 31, 2022 and 2021. Although the Company believes that the disclosures made in these interim financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with US GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”). The accompanying interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K Principles of Consolidation and Business Segments The consolidated financial statements include the accounts of iCAD, Inc. and its wholly owned subsidiaries: Xoft, Inc., Xoft Solutions, LLC, and iCAD France, LLC. All material inter-company transactions and balances have been eliminated in consolidation. The Company reports the results of tw Risk and Uncertainty On March 12, 2020, the World Health Organization declared COVID-19 COVID-19 COVID-19. COVID-19 COVID-19 COVID-19 COVID-19; including significant shifts in workforce availability and priorities, on customer, supplier, and iCAD’s business processes; and effects on healthcare customers and potential customers of pandemic related supply chain issues. The Company’s quarterly results for the quarter ending June 30, 2022, and possibly future quarters, could reflect a continuing negative impact from the COVID-19 Although the Company did not see any material impact to trade accounts receivable losses in the three-month period ended March 31, 2022, the Company’s exposure may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 COVID-19 Economic, civil, military and political uncertainty may arise or increase in regions where the Company operates or derives revenue. Further, countries from which the Company derives revenue may experience military action and/or civil and political unrest; may be subject to government export controls, economic sanctions, embargoes, or trade restrictions; and experience currency, inflation, and interest rate uncertainties. For the fiscal year ended 2021, approximately 8.6% of the Company’s total revenue and approximately 39.0% of the Company’s export revenue was derived from customers located in Europe. In late February 2022, Russian military forces launched significant military action against Ukraine. Sustained conflict and disruption in the region is likely. The aggregate impact to Eastern Europe and Europe as a whole, as well as actions taken by other countries, including new and stricter sanctions by the United States, Canada, the United Kingdom, the European Union, and other countries and organizations against officials, individuals, regions, and industries in Russia, Belarus and Ukraine, and each country’s potential response to such sanctions, tensions and military actions, is not knowable at this time, and could have a material adverse effect on the Company, its business and operations. Any such material adverse effect from the conflict and enhanced sanctions activity may disrupt the Company’s sales to customers in the region. Prolonged unfavorable economic conditions or uncertainty may have an adverse effect on the Company’s sales and profitability. Recently Adopted Accounting Pronouncements On January 1, 2022, the Company adopted ASU No. 2020-06, Debt—Debt 470-20) 815-40)—Accounting 2020-06”).” 2020-06 Recently Issued Accounting Standards In June 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU 2016-13, 2016-13”), 2016-13 2016-13 2016-13 2016-13

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 2 - Fair Value Measurements The Company follows the provisions of FASB ASC Topic 820, “ Fair Value Measurement and Disclosures • Level 1 - Quoted prices in active markets for identical assets or liabilities. • Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value The assigned level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Money market funds included in cash and cash equivalents in the accompanying consolidated balance sheet are considered a Level 1 measurement as they are valued at quoted market prices in active markets. The following table sets forth the Company’s assets which are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousand): Fair Value Measurements (in thousands) as of March 31, 2022 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 24,235 — — $ 24,235 Total Assets $ 24,235 — — $ 24,235 Fair Value Measurements (in thousands) as of December 31, 2021 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 30,573 — — $ 30,573 Total Assets $ 30,573 — — $ 30,573 There were no Level 3 instruments measured at fair value as of March 31, 2022 or December 31, 2021.

Revenue

Revenue	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue	Note 3 - Revenue Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration which the Company expects to be entitled to receive in exchange for these goods or services and excludes any sales incentives or taxes collected from customers which are subsequently remitted to government authorities. Disaggregation of Revenue The following tables presents the Company’s revenues disaggregated by major good or service line, timing of revenue recognition, and sales channel, reconciled to its reportable segments (in thousands). Three months ended March 31, 2022 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 3,864 $ 696 $ 4,560 Service 1,657 386 2,043 Sources and source usage agreements — 413 413 Disposable applicators — 415 415 Other — 92 92 $ 5,521 $ 2,002 $ 7,523 Timing of Revenue Recognition Goods transferred at a point in time $ 3,881 $ 1,264 $ 5,145 Services transferred over time 1,640 738 2,378 $ 5,521 $ 2,002 $ 7,523 Sales Channels Direct sales force $ 2,895 $ 815 $ 3,710 OEM partners 2,626 — 2,626 Channel partners — 1,187 1,187 $ 5,521 $ 2,002 $ 7,523 Three months ended March 31, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 4,161 $ 1,396 $ 5,557 Service 1,558 350 1,908 Sources and source usage agreements — 629 629 Disposable applicators — 495 495 Other — 55 55 $ 5,719 $ 2,925 $ 8,644 Timing of Revenue Recognition Goods transferred at a point in time $ 4,161 $ 2,104 $ 6,265 Services transferred over time 1,558 821 2,379 $ 5,719 $ 2,925 $ 8,644 Sales Channels Direct sales force $ 3,875 $ 674 $ 4,549 OEM partners 1,844 — 1,844 Channel partners — 2,251 2,251 $ 5,719 $ 2,925 $ 8,644 Products Service Sources and Source Usage Agreements Disposable applicators Other Contract Balances Contract liabilities are a component of deferred revenue, current contract assets are a component of prepaid and other assets and non-current non-current Balance at Balance at Receivables, which are included in ‘Trade accounts receivable’ $ 10,309 $ 8,891 Current contract assets, which are included in “Prepaid and other assets” $ 1,174 $ 1,895 Non-current $ 49 $ 844 Contract liabilities, which are included in “Deferred revenue” $ 6,336 $ 6,093 Timing of revenue recognition may differ from timing of invoicing of customers. The Company records a receivable when revenue is recognized prior to receipt of cash payment and the Company has the unconditional right to such consideration, or unearned revenue when cash payments are received or due in advance of performance. For multi-year agreements, the Company generally invoices customers annually at the beginning of each annual service period. The Company records net contract assets or contract liabilities on a contract-by-contract non-current non-current Changes in deferred revenue from contracts with customers were as follows (in thousands): Three Months Balance at beginning of period $ 6,093 Deferral of revenue 2,940 Recognition of deferred revenue (2,697 ) Balance at end of period $ 6,336 The Company expects to recognize estimated revenues related to performance obligation that are unsatisfied (or partially satisfied) in the amounts of approximately $5.9 million in 2022, $2.2 million in 2023, $1.3 million in 2024, and $1.1 million in 2025.

Net Loss per Common Share

Net Loss per Common Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss per Common Share	Note 4 – Net Loss per Common Share The Company’s basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. A summary of the Company’s calculation of net loss per share is as follows (in thousands except per share amounts): Three Months Ended March 31, 2022 2021 Net loss $ (3,545) $ (1,643) Shares used in the calculation of basic and diluted net loss per share 25,160 23,929 Diluted shares used in the calculation of net loss per share 25,160 23,929 Net loss per share—basic and diluted $ (0.14 ) $ (0.07 ) The shares of the Company’s common stock issuable upon the exercise of stock options and vesting of restricted stock that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive are as follows: As of March 31, 2022 2021 Stock options 2,894,449 2,246,776 Restricted stock — 31,654 Total 2,894,449 2,278,430

Inventories

Inventories	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Inventories	Note 5 – Inventories The Company values its inventory at the lower of cost or net realizable value. Cost includes materials, labor, and manufacturing overhead and is determined using the first-in, first-out March 31, 2022 December 31, 2021 Raw materials $ 3,333 $ 2,962 Work in process 504 173 Finished Goods 1,174 1,279 Inventory Gross 5,011 4,414 Inventory Reserve (275 ) (243 ) Inventory Net $ 4,736 $ 4,171

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Note 6 - Goodwill The Company tests goodwill for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of the reporting unit is less than its carrying value. There were no impairment indicators present as of March 31, 2022. Factors the Company considers important, which could trigger an impairment of such asset, include the following: • significant underperformance relative to historical or projected future operating results; • significant changes in the manner or use of the assets or the strategy for the Company’s overall business; • significant negative industry or economic trends; • significant decline in the Company’s stock price for a sustained period; and • a decline in the Company’s market capitalization below net book value.

Long-lived assets

Long-lived assets	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Long-lived assets	Note 7 – Long-lived Assets The Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than its carrying value. There is no set interval or frequency for recoverability evaluation. Rather, the determination of when, if at all, an asset (or asset group) is evaluated for recoverability is based on “events and circumstances.” The following factors are examples of events or changes in circumstances that indicate the carrying amount of an asset (or asset group) may not be recoverable and thus is to be evaluated for recoverability. • A significant decrease in the market price of a long-lived asset (or asset group); • A significant adverse change in the extent or manner in which a long-lived asset (or asset group) is being used or in its physical condition; • A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (or asset group), including an adverse action or assessment by a regulator; • An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (or asset group); and • A current operating period, or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (or asset group). The Company determined there were no such triggering events in the quarter ended March 31, 2022.

Leases Commitments

Leases Commitments	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Lease Commitments	Note 8 – Lease Commitments Per ASC 842, the Company determines if an arrangement contains a lease at inception. A lease is an operating or financing contract, or part of a contract, that conveys the right to control the use of an identified tangible asset for a period of time in exchange for consideration. At lease inception, the Company recognizes a lease liability equal to the present value of the remaining lease payments, and a right of use asset equal to the lease liability, subject to certain adjustments, such as for lease incentives. In determining the present value of the lease payments, the Company uses its incremental borrowing rate, determined by estimating the Company’s applicable, fully collateralized borrowing rate, with adjustment as appropriate for lease term. The lease term at the lease commencement date is determined based on the non-cancellable Right-of-use non-lease non-lease ASC 842 includes a number of reassessment and re-measurement right-of-use Certain of the Company’s leases include variable lease costs to reimburse the lessor for real estate tax and insurance expenses, and certain non-lease non-lease Components of Leases: The Company has leases for office space and office equipment. The leases expire at various dates through 2024. Lease Cost Classification Three Months Operating lease cost—Right of Use Asset Operating expenses $ 215 Operating lease cost—Variable Operating expenses 61 Total $ 276 Other information related to leases was as follows (in thousands): Three Months Cash paid from operating cash flows for operating leases $ 229 As of March 31, Weighted-average remaining lease term of operating leases (in year) 1.02 Weighted-average discount rate for operating leases 5.5 % Maturity of the Company’s lease liabilities as of March 31, 2022 was as follows (in thousands): 2022 701 2023 253 2024 16 Total lease payments 970 Less: imputed interest (29 ) Total lease liabilities 941 Less: current portion of lease liabilities (887 ) Long-term lease liabilities $ 54

Notes Payable

Notes Payable	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Notes Payable	Note 9 – Notes Payable (a) Loan and Security Agreement – Western Alliance Bank On March 30, 2020, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Western Alliance Bank (the “Bank”) that provided an initial term loan (“Term Loan”) facility of $7.0 million and a $5.0 million revolving line of credit. Obligations to the Bank under the Loan Agreement were secured by a first priority security interest in the Company’s assets, except for certain permitted liens that have priority to the Bank’s security interest by operation of law. On April 27, 2021, the Company repaid its obligations in the aggregate amount of $7,354,283 and terminated the Loan Agreement with the Bank, and the Company’s collateral securing the facility was released. The Company accounted for this repayment and retirement as an extinguishment of the Loan Agreement. The Company recorded a loss on extinguishment of approximately $386,000 at that time related to the repayment and retirement of the Loan Agreement. The loss on extinguishment was composed of approximately $140,000 for a prepayment fee, $122,000 for the unaccrued final payment, $65,000 termination and other fees, and $58,000 for the unamortized discount and other closing costs from origination of the loan. The following amounts are included in interest expense related to the Loan Agreement in the Company’s consolidated statement of operations for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended March 31, 2022 2021 Cash interest expense $ — $ 92 Accrual of notes payable final payment — 7 Amortization of debt costs — 13 Total interest expense $ — $ 112

Stockholders Equity

Stockholders Equity	3 Months Ended
	Mar. 31, 2022
Federal Home Loan Banks [Abstract]
Stockholders Equity	Note 10 – Stockholders Equity (a) Financing Activity On March 2, 2021, the Company entered into an underwriting agreement with Guggenheim Securities, LLC, as representative of the several underwriters thereto, in connection with an underwritten public offering of 1,393,738 shares of the Company’s common stock at an offering price of $18.00 per share. The Offering closed on March 5, 2021 for gross proceeds of approximately $25.1 million and net proceeds of approximately $23.2 million to the Company. (b) Stock-Based Compensation The Company granted options to purchase up to an aggregate of 675,000 shares of the Company’s stock during the three months ended March 31, 2022. Options granted under the Company’s stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values: Three Months Ended 2022 2021 Average risk-free interest rate 1.46% 0.20% Expected dividend yield None None Expected life 3.5 years 3.5 years Expected volatility 66.3% to 69.5% 66.0% to 66.0% Weighted average exercise price $5.22 $18.00 Weighted average fair value $2.56 $8.37 The Company’s stock-based compensation expense, including options and restricted stock by category is as follows (amounts in thousands): Three Months Ended 2022 2021 Cost of revenue $ — $ 14 Engineering and product development 68 149 Marketing and sales 199 353 General and administrative 388 419 $ 655 $ 935 As of March 31, 2022, there was approximately $3.9 million of total unrecognized compensation cost related to unvested options and restricted stock. That cost is expected to be recognized over a weighted average period of 1.82 years. The Company granted 0 and 22,488 shares of restricted stock during the three-month periods ended March 31, 2022 and 2021, respectively. The Company’s restricted stock awards typically vest in either one year or three equal annual installments with the first installment vesting one year from the grant date. All of the Company’s restricted stock grants in 2021 had time-based vesting requirements The grant date fair value for restricted stock awards is based on the quoted market value of Company stock on the grant date. The Company’s aggregate intrinsic value for stock options and restricted stock outstanding is as follows (in thousands): As of March 31, Aggregate intrinsic value 2022 2021 Stock options $ 1,311 $ 29,305 Restricted stock — 672 The Company issued 22,833 shares of common stock upon the exercise of outstanding stock options in the three-month period ended March 31, 2022. The Company received cash proceeds of approximately $66,000 in the three -month period ended March 31, 2022. The intrinsic value of 20,000 restricted shares that vested in the three months ended March 31, 2021 was $0.3 million. Employee Stock Purchase Plan In December 2019, the 2019 Employee Stock Purchase Plan (“ESPP”) was adopted by the Company’s Board of Directors (the “Board”) and approved by stockholders, effective January 1, 2020. The ESPP provides for the issuance of up to 950,000 shares of common stock, subject to adjustment in the event of a stock split, stock dividend or other change in the Company’s capitalization. The ESPP may be terminated or amended by the Board at any time. Certain amendments to the ESPP require stockholder approval. Substantially all of the Company’s employees whose customary employment is for more than 20 hours a week are eligible to participate in the ESPP. Any employee who owns 5% or more of the voting power or value of the Company’s shares of common stock is not eligible to participate in the ESPP. Any eligible employee can enroll in the ESPP as of the beginning of a respective quarterly accumulation period. Employees who participate in the ESPP may purchase shares by authorizing payroll deductions of up to 15% of their base compensation during an accumulation period. Unless the participating employee withdraws from participation, accumulated payroll deductions are used to purchase shares of common stock on the last business day of the accumulation period (the “Purchase Date”) at a price equal to 85% of the lower of the fair market value on (i) the Purchase Date or (ii) the first day of such accumulation period. Under applicable tax rules, no employee may purchase more than $25,000 worth of common stock, valued at the start of the purchase period, under the ESPP in any calendar year. The Company issued 9,381 shares under the ESPP in the three-month period ended March 31, 2022. The Company recorded approximately $10,000 of stock-based compensation expense pursuant to ESPP for the three-month period ended March 31, 2022. The next accumulation period under the ESPP commenced on January 31, 2022 and ended on March 31, 2022, and the related shares purchased by the participants were issued in April 2022. As of March 31, 2022, the Company recorded a liability of approximately $33,000 related to employee withholdings in connection with the ESPP accumulation period ended March 31, 2022, which was included as a component of accrued expenses and other current liabilities.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 11 - Income Taxes The Company had no material unrecognized tax benefits and a deferred tax liability of approximately $6,000 related to tax amortizable goodwill at March 31, 2022. No other adjustments were required under ASC 740, “Income Taxes.” The Company does not expect that its unrecognized tax benefits will materially increase within the next 12 months. The Company did not recognize any interest or penalties related to uncertain tax positions at March 31, 2022. The Company files United States federal income tax returns and income tax returns in various states and local jurisdictions. The Company’s three preceding tax years remain subject to examination by federal and state tax authorities. In addition, because the Company has net operating loss carry-forwards, the Internal Revenue Service and state jurisdictions are permitted to audit earlier years and propose adjustments up to the amount of net operating loss generated in those years. The Company is not currently under examination by any federal or state jurisdiction for any tax years.

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Segment Reporting	Note 12 – Segment Reporting Operating segments are the components of the Company’s business for which separate financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM is the chief executive officer. The Company’s operating segments are generally organized by the type of product or service offered and by geography. The Detection segment consists of the Company’s advanced image analysis and workflow products, and the Therapy segment consists of the Company’s radiation therapy products, and related services. The primary factors used by the Company’s CODM to allocate resources are based on revenues, gross profit, operating income or loss, and earnings or loss before interest, taxes, depreciation, amortization, and other specific and non-recurring The Company does not track its assets by operating segment and the CODM does not use asset information by segment to allocate resources or make operating decisions. Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows (in thousands): Three Months Ended 2022 2021 Segment revenues: Detection $ 5,521 $ 5,719 Therapy 2,002 2,925 Total Revenue $ 7,523 $ 8,644 Segment gross profit: Detection $ 4,661 $ 4,725 Therapy 651 1,564 Segment gross profit $ 5,312 $ 6,289 Segment operating income (loss): Detection $ 622 $ 941 Therapy (1,209 ) (312 ) Segment operating income (loss) $ (587 ) $ 629 General, administrative, depreciation and amortization expense $ (2,935 ) $ (2,162 ) Interest expense (9 ) (112 ) Other (expense) income (13 ) 2 Loss before income tax $ (3,544 ) $ (1,643 )

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 13 – Commitments and Contingencies Other Commitments The Company is obligated to pay approximately $5.8 million for firm purchase obligations to suppliers for future product and service deliverables and $0.2 million for minimum royalty obligations. Litigation The Company may be a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it the ultimate resolution of which would have a material adverse effect on its financial condition or results of operations, other than as set forth above. However, should the Company fail to prevail in any legal matter or should several legal matters be resolved against the Company in the same reporting period, such matters could have a material adverse effect on the Company’s operating results and cash flows for that particular period. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, “Contingencies.” Legal costs are expensed as incurred.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 14 – Subsequent Events The Company has evaluated events and transactions subsequent to the balance sheet date to the date of the filing and is not aware of any events or transactions that occurred subsequent to the balance sheet date that would require recognition or disclosure in the consolidated financial statements.

Organization and Business (Poli

Organization and Business (Policies)	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements of iCAD, Inc. and its subsidiaries (together “iCAD” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting period and disclosure of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. It is reasonably possible that changes may occur in the near term that would affect management’s estimates with respect to assets and liabilities. In the opinion of the Company’s management, these unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position of the Company at March 31, 2022, the results of operations of the Company for the three-month periods ended March 31, 2022 and 2021, cash flows of the Company for the three-month periods ended March 31, 2022 and 2021, and stockholders’ equity for the Company for the three-month periods ended March 31, 2022 and 2021. Although the Company believes that the disclosures made in these interim financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with US GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”). The accompanying interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K
Principles of Consolidation and Business Segments	Principles of Consolidation and Business Segments The consolidated financial statements include the accounts of iCAD, Inc. and its wholly owned subsidiaries: Xoft, Inc., Xoft Solutions, LLC, and iCAD France, LLC. All material inter-company transactions and balances have been eliminated in consolidation. The Company reports the results of tw
Risk and Uncertainty	Risk and Uncertainty On March 12, 2020, the World Health Organization declared COVID-19 COVID-19 COVID-19. COVID-19 COVID-19 COVID-19 COVID-19; including significant shifts in workforce availability and priorities, on customer, supplier, and iCAD’s business processes; and effects on healthcare customers and potential customers of pandemic related supply chain issues. The Company’s quarterly results for the quarter ending June 30, 2022, and possibly future quarters, could reflect a continuing negative impact from the COVID-19 Although the Company did not see any material impact to trade accounts receivable losses in the three-month period ended March 31, 2022, the Company’s exposure may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 COVID-19 Economic, civil, military and political uncertainty may arise or increase in regions where the Company operates or derives revenue. Further, countries from which the Company derives revenue may experience military action and/or civil and political unrest; may be subject to government export controls, economic sanctions, embargoes, or trade restrictions; and experience currency, inflation, and interest rate uncertainties. For the fiscal year ended 2021, approximately 8.6% of the Company’s total revenue and approximately 39.0% of the Company’s export revenue was derived from customers located in Europe. In late February 2022, Russian military forces launched significant military action against Ukraine. Sustained conflict and disruption in the region is likely. The aggregate impact to Eastern Europe and Europe as a whole, as well as actions taken by other countries, including new and stricter sanctions by the United States, Canada, the United Kingdom, the European Union, and other countries and organizations against officials, individuals, regions, and industries in Russia, Belarus and Ukraine, and each country’s potential response to such sanctions, tensions and military actions, is not knowable at this time, and could have a material adverse effect on the Company, its business and operations. Any such material adverse effect from the conflict and enhanced sanctions activity may disrupt the Company’s sales to customers in the region. Prolonged unfavorable economic conditions or uncertainty may have an adverse effect on the Company’s sales and profitability.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements On January 1, 2022, the Company adopted ASU No. 2020-06, Debt—Debt 470-20) 815-40)—Accounting 2020-06”).” 2020-06 Recently Issued Accounting Standards In June 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU 2016-13, 2016-13”), 2016-13 2016-13 2016-13 2016-13

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Assets and Liabilities which are Measured at Fair Value on a Recurring Basis	The following table sets forth the Company’s assets which are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousand): Fair Value Measurements (in thousands) as of March 31, 2022 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 24,235 — — $ 24,235 Total Assets $ 24,235 — — $ 24,235 Fair Value Measurements (in thousands) as of December 31, 2021 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 30,573 — — $ 30,573 Total Assets $ 30,573 — — $ 30,573

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenues Disaggregated by Major Good or Service Line, Timing of Revenue Recognition, and Sales Channel, Reconciled to Our Reportable Segments	The following tables presents the Company’s revenues disaggregated by major good or service line, timing of revenue recognition, and sales channel, reconciled to its reportable segments (in thousands). Three months ended March 31, 2022 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 3,864 $ 696 $ 4,560 Service 1,657 386 2,043 Sources and source usage agreements — 413 413 Disposable applicators — 415 415 Other — 92 92 $ 5,521 $ 2,002 $ 7,523 Timing of Revenue Recognition Goods transferred at a point in time $ 3,881 $ 1,264 $ 5,145 Services transferred over time 1,640 738 2,378 $ 5,521 $ 2,002 $ 7,523 Sales Channels Direct sales force $ 2,895 $ 815 $ 3,710 OEM partners 2,626 — 2,626 Channel partners — 1,187 1,187 $ 5,521 $ 2,002 $ 7,523 Three months ended March 31, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 4,161 $ 1,396 $ 5,557 Service 1,558 350 1,908 Sources and source usage agreements — 629 629 Disposable applicators — 495 495 Other — 55 55 $ 5,719 $ 2,925 $ 8,644 Timing of Revenue Recognition Goods transferred at a point in time $ 4,161 $ 2,104 $ 6,265 Services transferred over time 1,558 821 2,379 $ 5,719 $ 2,925 $ 8,644 Sales Channels Direct sales force $ 3,875 $ 674 $ 4,549 OEM partners 1,844 — 1,844 Channel partners — 2,251 2,251 $ 5,719 $ 2,925 $ 8,644
Summary of Receivables, Contract Assets and Contract Liabilities from Contracts with Customers	The following table provides information about receivables, current and non-current Balance at Balance at Receivables, which are included in ‘Trade accounts receivable’ $ 10,309 $ 8,891 Current contract assets, which are included in “Prepaid and other assets” $ 1,174 $ 1,895 Non-current $ 49 $ 844 Contract liabilities, which are included in “Deferred revenue” $ 6,336 $ 6,093
Summary of Changes in Deferred Revenue	Changes in deferred revenue from contracts with customers were as follows (in thousands): Three Months Balance at beginning of period $ 6,093 Deferral of revenue 2,940 Recognition of deferred revenue (2,697 ) Balance at end of period $ 6,336

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Calculation of Net Loss Per Share	A summary of the Company’s calculation of net loss per share is as follows (in thousands except per share amounts): Three Months Ended March 31, 2022 2021 Net loss $ (3,545) $ (1,643) Shares used in the calculation of basic and diluted net loss per share 25,160 23,929 Diluted shares used in the calculation of net loss per share 25,160 23,929 Net loss per share—basic and diluted $ (0.14 ) $ (0.07 )
Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share	The shares of the Company’s common stock issuable upon the exercise of stock options and vesting of restricted stock that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive are as follows: As of March 31, 2022 2021 Stock options 2,894,449 2,246,776 Restricted stock — 31,654 Total 2,894,449 2,278,430

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Current Inventory	March 31, 2022 December 31, 2021 Raw materials $ 3,333 $ 2,962 Work in process 504 173 Finished Goods 1,174 1,279 Inventory Gross 5,011 4,414 Inventory Reserve (275 ) (243 ) Inventory Net $ 4,736 $ 4,171

Leases Commitments (Tables)

Leases Commitments (Tables)	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Components of Lease Expense	The Company has leases for office space and office equipment. The leases expire at various dates through 2024. Lease Cost Classification Three Months Operating lease cost—Right of Use Asset Operating expenses $ 215 Operating lease cost—Variable Operating expenses 61 Total $ 276 Other information related to leases was as follows (in thousands): Three Months Cash paid from operating cash flows for operating leases $ 229 As of March 31, Weighted-average remaining lease term of operating leases (in year) 1.02 Weighted-average discount rate for operating leases 5.5 %
Summary of Detained Information of Lease Liabilities	Maturity of the Company’s lease liabilities as of March 31, 2022 was as follows (in thousands): 2022 701 2023 253 2024 16 Total lease payments 970 Less: imputed interest (29 ) Total lease liabilities 941 Less: current portion of lease liabilities (887 ) Long-term lease liabilities $ 54

Notes Payable (Table)

Notes Payable (Table)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Summary of Interest Expense in Consolidated Income Statement	The following amounts are included in interest expense related to the Loan Agreement in the Company’s consolidated statement of operations for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended March 31, 2022 2021 Cash interest expense $ — $ 92 Accrual of notes payable final payment — 7 Amortization of debt costs — 13 Total interest expense $ — $ 112

Stockholders Equity (Tables)

Stockholders Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values	Three Months Ended 2022 2021 Average risk-free interest rate 1.46% 0.20% Expected dividend yield None None Expected life 3.5 years 3.5 years Expected volatility 66.3% to 69.5% 66.0% to 66.0% Weighted average exercise price $5.22 $18.00 Weighted average fair value $2.56 $8.37
Stock-Based Compensation Expense Including Options and Restricted Stock by Category	The Company’s stock-based compensation expense, including options and restricted stock by category is as follows (amounts in thousands): Three Months Ended 2022 2021 Cost of revenue $ — $ 14 Engineering and product development 68 149 Marketing and sales 199 353 General and administrative 388 419 $ 655 $ 935
Aggregate Intrinsic Value	The Company’s aggregate intrinsic value for stock options and restricted stock outstanding is as follows (in thousands): As of March 31, Aggregate intrinsic value 2022 2021 Stock options $ 1,311 $ 29,305 Restricted stock — 672

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss	Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows (in thousands): Three Months Ended 2022 2021 Segment revenues: Detection $ 5,521 $ 5,719 Therapy 2,002 2,925 Total Revenue $ 7,523 $ 8,644 Segment gross profit: Detection $ 4,661 $ 4,725 Therapy 651 1,564 Segment gross profit $ 5,312 $ 6,289 Segment operating income (loss): Detection $ 622 $ 941 Therapy (1,209 ) (312 ) Segment operating income (loss) $ (587 ) $ 629 General, administrative, depreciation and amortization expense $ (2,935 ) $ (2,162 ) Interest expense (9 ) (112 ) Other (expense) income (13 ) 2 Loss before income tax $ (3,544 ) $ (1,643 )

Organization and Business - Add

Organization and Business - Additional Information (Detail) - Segment	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Number of Operating Segments	2
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | Europe [Member]
Concentration Risk, Percentage		8.60%
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | Europe [Member] | Revenue Through Exports [Member]
Concentration Risk, Percentage		39.00%

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities which are Measured at Fair Value on a Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Assets
Total Assets	$ 24,235	$ 30,573
Money Market Accounts [Member]
Assets
Total Assets	24,235	30,573
Level 1 [Member]
Assets
Total Assets	24,235	30,573
Level 1 [Member] | Money Market Accounts [Member]
Assets
Total Assets	$ 24,235	$ 30,573

Revenue - Revenues Disaggregate

Revenue - Revenues Disaggregated by Major Good or Service Line, Timing of Revenue Recognition, and Sales Channel, Reconciled to Our Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	$ 7,523	$ 8,644
Products [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	4,560	5,557
Service [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,043	1,908
Source and Source Usage Agreements [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	413	629
Disposal applicators [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	415	495
Other [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	92	55
Goods Transferred at a Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	5,145	6,265
Services Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,378	2,379
Direct Sales Force [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	3,710	4,549
OEM Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,626	1,844
Channel Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,187	2,251
Detection [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	5,521	5,719
Detection [Member] | Products [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	3,864	4,161
Detection [Member] | Service [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,657	1,558
Detection [Member] | Goods Transferred at a Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	3,881	4,161
Detection [Member] | Services Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,640	1,558
Detection [Member] | Direct Sales Force [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,895	3,875
Detection [Member] | OEM Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,626	1,844
Therapy [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,002	2,925
Therapy [Member] | Products [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	696	1,396
Therapy [Member] | Service [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	386	350
Therapy [Member] | Source and Source Usage Agreements [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	413	629
Therapy [Member] | Disposal applicators [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	415	495
Therapy [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	92	55
Therapy [Member] | Goods Transferred at a Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,264	2,104
Therapy [Member] | Services Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	738	821
Therapy [Member] | Direct Sales Force [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	815	674
Therapy [Member] | Channel Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	$ 1,187	$ 2,251

Revenue - Summary of Receivable

Revenue - Summary of Receivables, Contract Assets and Contract Liabilities from Contracts with Customers (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Contract with Customer, Asset and Liability [Abstract]
Receivables, which are included in ‘Trade accounts receivable'	$ 10,309	$ 8,891
Current contract assets, which are included in "Prepaid and other assets"	1,174	1,895
Non-current contract assets, which are included in "other assets"	49	844
Contract liabilities, which are included in "Deferred revenue"	$ 6,336	$ 6,093

Revenue - Summary of Changes in

Revenue - Summary of Changes in Deferred Revenue from Contracts with Customers (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Deferred Revenue Disclosure [Abstract]
Balance at beginning of period	$ 6,093
Deferral of revenue	2,940
Recognition of deferred revenue	(2,697)
Balance at end of period	$ 6,336

Revenue - Additional Informatio

Revenue - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)
Revenue From Contract With Customer [Line Items]
Unearned amount to recognize in 2022	$ 5.9
Unearned amount to recognize in 2023	2.2
Unearned amount to recognize in 2024	1.3
Unearned amount to recognize in 2025	$ 1.1

Net Loss per Common Share - Cal

Net Loss per Common Share - Calculation of Net Loss Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Net loss	$ (3,545)	$ (1,643)
Shares used in the calculation of basic and diluted net loss per share	25,160	23,929
Diluted shares used in the calculation of net loss per share	25,160	23,929
Net loss per share—basic and diluted	$ (0.14)	$ (0.07)

Net Loss per Common Share - Sch

Net Loss per Common Share - Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	2,894,449	2,278,430
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	2,894,449	2,246,776
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	0	31,654

Inventory - Schedule of Current

Inventory - Schedule of Current Inventory (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 3,333	$ 2,962
Work in process	504	173
Finished Goods	1,174	1,279
Inventory Gross	5,011	4,414
Inventory Reserve	(275)	(243)
Inventory	$ 4,736	$ 4,171

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventory reserve	$ 275	$ 243

Goodwill - Additional Informati

Goodwill - Additional Information (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill Impairment	$ 0

Leases Commitments - Schedule o

Leases Commitments - Schedule of Components of Lease Expense (Detail) - Accounting Standards Update 2016-02 [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Lessee, Lease, Description [Line Items]
Operating lease cost—Right of Use Asset	$ 215
Operating lease cost—Variable	61
Finance lease costs
Total	276
Cash paid from operating cash flows for operating leases	$ 229
Weighted-average remaining lease term of operating leases (in year)	1 year 7 days
Weighted-average discount rate for operating leases	5.50%

Leases Commitments - Summary of

Leases Commitments - Summary of Detained Information of Lease Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
2022	$ 701
2023	253
2024	16
Total	970
Less: imputed interest	(29)
Total lease liabilities	941
Less: current portion of lease liabilities	(887)
Total Long-term lease liabilities	$ 54	$ 266

Notes Payable - Summary of Inte

Notes Payable - Summary of Interest Expense in Consolidated Income Statement (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Interest Expense [Line Items]
Total interest expense	$ 9	$ 112
Western Alliance Bank [Member]
Interest Expense [Line Items]
Cash interest expense	0	92
Accrual of notes payable final payment	0	7
Amortization of debt costs	0	13
Total interest expense	$ 0	$ 112

Notes Payable - Additional Info

Notes Payable - Additional Information (Detail) - USD ($) $ in Thousands	Apr. 27, 2021	Mar. 31, 2022	Mar. 30, 2020
Debt Instrument [Line Items]
Repayments of Lines of Credit	$ 7,354,283
Western Alliance Bank [Member]
Debt Instrument [Line Items]
Gain (Loss) on Extinguishment of Debt		$ 386,000
Western Alliance Bank [Member] | Debt Prepayment Cost [Member]
Debt Instrument [Line Items]
Debt prepayment cost		140,000
Western Alliance Bank [Member] | Final Payment Of Loan [Member]
Debt Instrument [Line Items]
Final Payment of Loan		122,000
Western Alliance Bank [Member] | Termination Loans [Member]
Debt Instrument [Line Items]
Termination Loans		65,000
Western Alliance Bank [Member] | Unamortized Debt Issuance Expense [Member]
Debt Instrument [Line Items]
Unamortized closing costs		$ 58,000
Term Loan A [Member] | Western Alliance Bank [Member]
Debt Instrument [Line Items]
Credit facility			$ 7,000
Revolving Credit Facility [Member] | Western Alliance Bank [Member]
Debt Instrument [Line Items]
Credit facility			$ 5,000

Stockholders Equity - Options G

Stockholders Equity - Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values (Detail) - Stock Options [Member] - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average risk-free interest rate	1.46%	0.20%
Expected dividend yield	0.00%	0.00%
Expected life	3 years 6 months	3 years 6 months
Weighted average exercise price	$ 5.22	$ 18
Weighted average fair value	$ 2.56	$ 8.37
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	66.30%	66.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	69.50%	66.00%

Stockholders Equity - Stock-Bas

Stockholders Equity - Stock-Based Compensation Expense Including Options and Restricted Stock by Category (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$ 655	$ 935
Cost of Revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	0	14
Engineering and Product Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	68	149
Marketing and Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	199	353
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$ 388	$ 419

Stockholders Equity - Aggregate

Stockholders Equity - Aggregate Intrinsic Value (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option	$ 1,311	$ 29,305
Restricted stock	$ 0	$ 672

Stockholders Equity - Additiona

Stockholders Equity - Additional Information (Detail) - USD ($)	Mar. 02, 2021	Dec. 31, 2019	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Net proceeds from Issue of common stock			$ 0	$ 23,229,000
Underwritten public offering shares	1,393,738
Offering price, per share	$ 18
Gross proceeds from sale of units	$ 25,100,000
Net proceeds from sale of units	$ 23,200,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized			$ 3,900,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			1 year 9 months 25 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option Granted			0	22,488
Number of shares vested			20,000
Intrinsic value of restricted shares that vested			$ 300,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, Issued			22,833
Net proceeds from Issue of common stock			$ 66,000
2019 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of voting power		5.00%
Description of employee stock purchase plan			Employees who participate in the ESPP may purchase shares by authorizing payroll deductions of up to 15% of their base compensation during an accumulation period. Unless the participating employee withdraws from participation, accumulated payroll deductions are used to purchase shares of common stock on the last business day of the accumulation period (the “Purchase Date”) at a price equal to 85% of the lower of the fair market value on (i) the Purchase Date or (ii) the first day of such accumulation period. Under applicable tax rules, no employee may purchase more than $25,000 worth of common stock, valued at the start of the purchase period, under the ESPP in any calendar year.
Number of shares issued, Employee Stock Purchase Plans		950,000	9,381
Stock-based compensation expense			$ 10,000
Employee-related Liabilities, Current			$ 33,000
Black Scholes Model [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option Granted			675,000

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail)	Mar. 31, 2022USD ($)
Schedule Of Income Tax Expense [Line Items]
Unrecognized tax benefits	$ 0
Deferred Tax Liabilities, Goodwill	$ 6,000

Segment Reporting - Summary of

Segment Reporting - Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Segment revenues:
Total Revenue	$ 7,523	$ 8,644
Segment gross profit:
Segment gross profit	5,312	6,289
Segment operating income (loss):
Segment operating income (loss)	(587)	629
General, administrative, depreciation and amortization expense	(2,935)	(2,162)
Interest expense	(9)	(112)
Other (expense) income	(13)	2
Loss before income tax expense	(3,544)	(1,643)
Product [Member]
Segment revenues:
Total Revenue	4,560	5,557
Service [Member]
Segment revenues:
Total Revenue	2,963	3,087
Detection [Member]
Segment gross profit:
Segment gross profit	4,661	4,725
Segment operating income (loss):
Segment operating income (loss)	622	941
Detection [Member] | Product [Member]
Segment revenues:
Total Revenue	5,521	5,719
Therapy [Member]
Segment gross profit:
Segment gross profit	651	1,564
Segment operating income (loss):
Segment operating income (loss)	(1,209)	(312)
Therapy [Member] | Service [Member]
Segment revenues:
Total Revenue	$ 2,002	$ 2,925

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2022Segment
Schedule Of Geographical Information [Line Items]
Number of reporting segments	2

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Millions	Mar. 31, 2022USD ($)
Schedule Of Leases [Line Items]
Purchase obligations to suppliers for future product deliverables	$ 5.8
Minimum royalty obligations	$ 0.2